The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years.
“Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.”
The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs.
It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval.
Related articles:
Related suggestion:
China to launch new research project on giant panda protectionTop of Eiffel Tower reopens to publicXi Inspects Nanning in South China's GuangxiExpert warns return to lockdown conditions a possibility in B.C., CanadaChinese FM attends reception marking 60th anniversary of ChinaMalta, Libya pledge to cooperate to save lives at seaWorld's highest pumped storage power station begins constructionPeople buy sheep at livestock market ahead of Eid alMayor of S.Korean capital Seoul found deadTop of Eiffel Tower reopens to public
0.2376s , 6503.1171875 kb
Copyright © 2024 Powered by Study: Many cancer drugs unproven 5 years after accelerated approval ,Worldly Wonders news portal